SYSCID

The SYSCID consortium aims to develop a systems medicine approach for predictions in chronic inflammatory diseases (CID). The overall goal is to create a prediction framework for disease outcome to guide therapy decisions on an individual patient level enabling the choice of the right therapy at the right time. Furthermore, the SYSCID consortium targets new therapy approaches by "reprogramming" disease through epigenome editing.

Registration numbers: HRB 12001 (W)

VAT numbers: DE 210372698

Primary location: St. Ingbert Germany